Ipsen S.A. (EPA:IPN)
France · Delayed Price · Currency is EUR | Market Cap | 13.71B +80.1% |
| Revenue (ttm) | 3.93B +9.9% |
| Net Income | 443.50M +28.2% |
| EPS | 5.32 +28.2% |
| Shares Out | 82.10M |
| PE Ratio | 31.39 |
| Forward PE | 12.20 |
| Dividend | 1.40 (0.84%) |
| Ex-Dividend Date | Jun 3, 2026 |
| Volume | 6,036 |
| Average Volume | 128,126 |
| Open | 166.70 |
| Previous Close | 167.00 |
| Day's Range | 165.30 - 166.70 |
| 52-Week Range | 99.00 - 170.80 |
| Beta | 0.32 |
| RSI | 58.45 |
| Earnings Date | Apr 23, 2026 |
About Ipsen
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injection for the treatment of pancreatic cancer; Decapeptyl for the treatment of advanced metastatic prostate cancer; Tazverik, a chemotherapy-free EZH2a i... [Read more]
Full Company ProfileFinancial Performance
In 2025, Ipsen's revenue was 3.93 billion, an increase of 9.92% compared to the previous year's 3.57 billion. Earnings were 443.50 million, an increase of 28.22%.
Financial StatementsNews
Ipsen Earnings Call Transcript: Q1 2026
Q1 2026 saw 22.6% sales growth, led by strong performance across all therapeutic areas and robust gains in rare disease and neuroscience. Guidance for 2026 is reaffirmed, with key pipeline milestones and generic competition for Somatuline expected in H2.
Ipsen: European Commission Grants Conditional Marketing Authorization For Ojemda
(RTTNews) - Ipsen (IPN.PA, I7G.F) announced that the European Commission has granted conditional marketing authorization for Ojemda as monotherapy for the treatment of patients 6 months of age and old...
Ipsen S.A. publishes its 2025 Consolidated Financial Statements
Ipsen S.A. publishes its 2025 Consolidated Financial Statements Attachment Ipsen_Consolidated financial statements 2025_GB
Ipsen Earnings Call Transcript: H2 2025
Double-digit sales and profit growth in 2025 were driven by strong performance across all therapeutic areas, with robust cash flow and a solid balance sheet supporting continued R&D and external innovation. 2026 guidance anticipates further double-digit growth, limited generic competition for Somatuline, and multiple regulatory milestones.
Ipsen Earnings Call Transcript: Q3 2025
Double-digit sales and margin growth led to upgraded 2025 guidance, with rare disease and neuroscience segments driving strong performance. Pipeline advances include the ImCheck acquisition and positive IPN10200 data, while Somatuline faces gradual generic erosion in 2026.
Ipsen S.A. publishes its 2025 Half-Year Report (half-year ended 30 June 2025)
Ipsen S.A. publishes its 2025 Half-Year Report (half-year ended 30 June 2025) Attachment 2025 Half-year Financial Report_Ipsen SA
Ipsen Earnings Call Transcript: H1 2025
H1 2025 saw 11.4% sales growth, margin expansion, and strong cash flow, prompting upgraded full-year guidance. Pipeline advances and new approvals, especially in oncology and rare disease, support continued growth, while Somatuline faces generic headwinds.
Ipsen S.A. - Initiation of the share buy-back program
Regulated information Ipsen initiates a share buy-back program to cover its free employee share-allocation plan PARIS, FRANCE, 2 June 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that ...
Ipsen S.A. - Annual General Meeting held on 21 May 2025
Annual General Meeting of Ipsen S.A. held on 21 May 2025 All the resolutions submitted to the shareholders' vote have been adopted PARIS, FRANCE, 21 May 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) announ...
Ipsen S.A. - Formalities for making available and consulting preparatory documents to the 2025 Annual General Meeting
Information relating to the holding of the Combined Shareholders' Meeting of 21 May 2025 of Ipsen S.A. Formalities for making available and consulting preparatory documents to the Meeting PARIS, FRANC...
Ipsen Earnings Call Transcript: Q1 2025
Q1 2025 sales rose 11.6% with strong growth across all segments, led by Bylvay and IQIRVO launches. Guidance for 2025 is reaffirmed, with Somatuline facing accelerated generic erosion and key pipeline milestones expected.
Ipsen delivers strong sales in the first quarter 2025 and confirms its full-year guidance
PARIS, FRANCE, 16 April 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents sales for the first quarter of 2025.
Ipsen Earnings Call Transcript: H2 2024
Sales grew 9.9% in 2024, with strong gains in oncology, rare disease, and neuroscience. 2025 guidance targets over 5% sales growth and a core margin above 30%, despite Somatuline generic erosion. Pipeline momentum and EUR 2.3B for innovation support future growth.
Ipsen Earnings Call Transcript: Q3 2024
Sales grew 8.6% in Q3 and 9.2% year-to-date, led by Dysport, Bylvay, and new launches Iqirvo and Onivyde. Full-year guidance was raised, with strong pipeline progress and continued investment expected to drive future growth.
Employee of French drugmaker Ipsen to plead guilty to US insider trading
An employee of French drugmaker Ipsen has agreed to plead guilty to illegally making more than $262,000 by trading on inside information he learned about his company's plans to acquire cancer drug dev...
Ipsen S.A. publishes its 2024 Half-Year Report (half-year ended 30 June 2024)
Ipsen S.A. publishes its 2024 Half-Year Report (half-year ended 30 June 2024) Attachment 2024 Ipsen Half-Year Financial Report
Ipsen Earnings Call Transcript: H1 2024
Sales grew 9.5% in H1 2024, driven by strong launches and pipeline progress. Upgraded guidance expects over 7% sales growth for the year, with margin pressure anticipated in H2 due to investments and generic competition.
Annual General Meeting of Ipsen S.A. held on 28 May 2024
PARIS, FRANCE, 28 May 2024 - The Annual General Meeting of Ipsen S.A. (Euronext: IPN; ADR: IPSEY) was held today at the Salons de l'Hôtel des Arts et Métiers, 9 bis, avenue d'Iéna, 75116 Paris (France...
Description of the regulatory framework of the share repurchase program proposed by the Board of Directors to be approved at Ipsen S.A.'s Annual General Meeting on 28 May 2024
PARIS, FRANCE, 28 May 2024 - In accordance with the provisions of Article L.22-10-62 et seq. of the French Commercial Code, the European Regulation (EU) No 596/2014 of the European Parliament and of t...
Ipsen S.A. - Formalities for making available and consulting preparatory documents to the 2024 Annual General Meeting
Information relating to the holding of the Combined Shareholders' Meeting of 28 May 2024 of Ipsen S.A. Formalities for making available and consulting preparatory documents to the Meeting BOULOGNE-BIL...
Ipsen Earnings Call Transcript: Q1 2024
Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance
PARIS, FRANCE, 24 April 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the first quarter of 2024.
Ipsen S.A. publishes its 2023 Consolidated Financial Statements
Ipsen S.A. - 2023 Consolidated Financial Statements Attachment Ipsen - 2023 Consolidated Financial Statements